Insight, China's Pharmaceutical Industry

Shandong Jincheng Pharma Subsidiary Jincheng Taier to Sell Proxyl Vaginal Capsule Tech & MAH Rights to Shanghai Hemony for RMB 50 M

Shandong Jincheng Pharmaceutical Group Co., Ltd. (SHE: 300233) disclosed that its wholly‑owned subsidiary Jincheng Taier...

Company Drug

Sinotau Receives FDA NDA Approval for MK‑6240 Tau PET Imaging Agent

Fineline Cube Nov 6, 2025

Beijing Sinotau International Pharmaceutical Technology Co., Ltd. announced today that the New Drug Application (NDA) for...

Company Deals

Baheal Pharma Locks CSL Behring Albumin Rights to Boost China’s Blood Product Supply

Fineline Cube Nov 6, 2025

Baheal Pharma Group (SHE: 301015), a prominent Chinese therapeutic manufacturer, announced an enhanced cooperation agreement...

Company Deals

Prelude Therapeutics Revamps Pipeline: Incyte Option on JAK2V617F, KAT6A Degrader Takes Center Stage, SMARCA2 Paused

Fineline Cube Nov 5, 2025

Prelude Therapeutics (NASDAQ: PRLD) unveiled a suite of strategic shifts: it signed an option deal...

Company Drug

UCB Wins FDA Approval for KYGEVVI in Rare Mitochondrial Disease TK2d

Fineline Cube Nov 5, 2025

UCB (EBR: UCB) announced that KYGEVVI received FDA approval for the treatment of adult and...

Company Drug

Dizal Highlights Breakthrough Findings for golidocitinib and birelentinib at ASH 2025

Fineline Cube Nov 5, 2025

Dizal Pharmaceutical Co., Ltd. (SHA: 688192) announced that multiple research updates for its two core...

Company Drug

Jiangsu Vcare’s VC004 Joins NMPA’s SPARK Oncology Program

Fineline Cube Nov 5, 2025

The Center for Drug Evaluation (CDE) under the National Medical Products Administration (NMPA) has officially...

Company

Pfizer’s Q3 2025 Results: COVID‑19 Sales Slide While Eliquis Soars

Fineline Cube Nov 5, 2025

US pharmaceutical heavyweight Pfizer Inc. (NYSE: PFE) posted Q3 2025 revenues of $16.7 B – a...

Company Drug

Jiangsu Hengrui Secures Priority Review for HRS‑5965 in China’s Rare‑Disease Portfolio

Fineline Cube Nov 5, 2025

Jiangsu Hengrui Pharmaceuticals (SHA: 600276, HKG: 1276) announced that the National Medical Products Administration (NMPA)...

Company Drug

Pluvicto Radioligand Therapy Receives Dual NMPA Approvals in China

Fineline Cube Nov 5, 2025

Novartis (NYSE: NVS) has announced that its Lutetium‑177‑labelled therapy Pluvicto (lutetium ¹⁷⁷Lu‑vipivotide tetraxetan) now holds...

Company Drug

Sichuan Biokin Secures Breakthrough Therapy Designation for HER2‑Targeted ADC T‑Bren

Fineline Cube Nov 5, 2025

China’s Sichuan Biokin Pharmaceutical Co., Ltd. (SHA: 688506) announced that its proprietary antibody‑drug conjugate (ADC)...

Company Drug

Shenzhen Kangtai Biological Products Launches Phase I Trial for Infant Influenza Vaccine

Fineline Cube Nov 5, 2025

China‑based Shenzhen Kangtai Biological Products Co., Ltd. (SHE: 300601) has entered the clinical stage with...

Company Deals

4D Molecular Transfers Asia‑Pacific Gene‑Therapy Rights to Otsuka for $85 M Cash

Fineline Cube Nov 5, 2025

4D Molecular Therapeutics (4DMT) sold the Asia‑Pacific rights to its eye‑gene therapy 4D‑150 to Otsuka...

Company

Novo Nordisk Reports 15 % YoY Sales Growth, Cuts Full‑Year Guidance

Fineline Cube Nov 5, 2025

Denmark‑based biopharma Novo Nordisk A/S (NYSE: NVO) disclosed Q1‑Q3 2025 financials that show a 15 %...

Policy / Regulatory

China CDE Opens Public Comment on 100th Batch of Reference Standards for Chemical Generic Drugs

Fineline Cube Nov 5, 2025

The China Center for Drug Evaluation (CDE) has released a draft list of the 100th...

Company Deals Drug

MSD Secures Full Global Rights to MK‑8690 After $150 Million Settlement with Falk Pharma

Fineline Cube Nov 5, 2025

Merck Sharp & Dohme Inc. (MSD, NYSE: MRK), through its 2023 acquisition of Prometheus BioSciences,...

Policy / Regulatory

China’s National Health Commission Launches “Silver‑Haired” Healthcare & Elderly‑Care Initiative

Fineline Cube Nov 5, 2025

The National Health Commission (NHC) has issued a formal notice to roll out the Silver‑Haired...

Policy / Regulatory

China’s National Health Commission Issues “AI + Healthcare” Implementation Opinions – Roadmap for 24 Standardized Applications

Fineline Cube Nov 5, 2025

The National Health Commission (NHC) today released the Implementation Opinions on Promoting and Standardizing the...

Company Drug

Zhejiang Acea Pharma Secures Conditional NMPA Approval for Olgotrelvir Sodium Capsules – First Dual‑Target COVID‑19 Oral Antiviral in China

Fineline Cube Nov 5, 2025

Zhejiang Acea Pharmaceutical Co., Ltd. announced that China’s National Medical Products Administration (NMPA) has granted...

Company Drug

Daiichi Sankyo’s Enhertu Wins CDE Acceptance for First‑Line HER2‑Positive Breast‑Cancer Indication in China

Fineline Cube Nov 5, 2025

Daiichi Sankyo Co., Ltd. (TYO: 4568) announced that China’s Center for Drug Evaluation (CDE) of...

Insight, China's Pharmaceutical Industry

Suzhou AsiFlyer Biotechnology Secures Exclusive Worldwide License from ShanghaiTech University for AI‑Designed Recombinant Botulinum Toxin Patent

Liaocheng University and Shanghai Maiboxing Biotechnology Sign RMB 19 Million Pact to Co‑Develop LCUGZ1007 – Next‑Generation E‑PDC Probody Drug Conjugate

China Biotech’s Panboron BNCT Hospital Signs Strategic Pact with OncoCare Cancer Centre HK – Launching Cross‑Border BNCT Oncology Cooperation

Guangdong Taienkang Completes Capital Increase in Procapzoom – Secures Exclusive China Rights to World‑First Ocular Surface Cell Therapy SZ018

HepaBio Therapeutics Raises Series A Strategic Funding From TriApex to Advance Organoid Technology and Next‑Generation Drug R&D Systems

Hengrui Pharmaceuticals Wins NMPA Clinical Trial Approval for SHR‑1179 – First‑in‑Class Biological Candidate for Weight Management

Hualan Bio Wins NMPA Clinical Trial Approval for Novel Influenza mRNA Vaccine – China’s Vaccine Major Pushes into mRNA Platform

Shandong Jincheng Pharma Subsidiary Jincheng Taier to Sell Proxyl Vaginal Capsule Tech & MAH Rights to Shanghai Hemony for RMB 50 M

Sinotau Receives FDA NDA Approval for MK‑6240 Tau PET Imaging Agent

Baheal Pharma Locks CSL Behring Albumin Rights to Boost China’s Blood Product Supply

Prelude Therapeutics Revamps Pipeline: Incyte Option on JAK2V617F, KAT6A Degrader Takes Center Stage, SMARCA2 Paused

UCB Wins FDA Approval for KYGEVVI in Rare Mitochondrial Disease TK2d

Dizal Highlights Breakthrough Findings for golidocitinib and birelentinib at ASH 2025

Jiangsu Vcare’s VC004 Joins NMPA’s SPARK Oncology Program

Pfizer’s Q3 2025 Results: COVID‑19 Sales Slide While Eliquis Soars

Jiangsu Hengrui Secures Priority Review for HRS‑5965 in China’s Rare‑Disease Portfolio

Pluvicto Radioligand Therapy Receives Dual NMPA Approvals in China

Sichuan Biokin Secures Breakthrough Therapy Designation for HER2‑Targeted ADC T‑Bren

Shenzhen Kangtai Biological Products Launches Phase I Trial for Infant Influenza Vaccine

4D Molecular Transfers Asia‑Pacific Gene‑Therapy Rights to Otsuka for $85 M Cash

Novo Nordisk Reports 15 % YoY Sales Growth, Cuts Full‑Year Guidance

China CDE Opens Public Comment on 100th Batch of Reference Standards for Chemical Generic Drugs

MSD Secures Full Global Rights to MK‑8690 After $150 Million Settlement with Falk Pharma

China’s National Health Commission Launches “Silver‑Haired” Healthcare & Elderly‑Care Initiative

China’s National Health Commission Issues “AI + Healthcare” Implementation Opinions – Roadmap for 24 Standardized Applications

Zhejiang Acea Pharma Secures Conditional NMPA Approval for Olgotrelvir Sodium Capsules – First Dual‑Target COVID‑19 Oral Antiviral in China

Daiichi Sankyo’s Enhertu Wins CDE Acceptance for First‑Line HER2‑Positive Breast‑Cancer Indication in China

You Missed

Hengrui Pharmaceuticals Wins NMPA Clinical Trial Approval for SHR‑1179 – First‑in‑Class Biological Candidate for Weight Management

Hualan Bio Wins NMPA Clinical Trial Approval for Novel Influenza mRNA Vaccine – China’s Vaccine Major Pushes into mRNA Platform

METiS Therapeutics Partners with Hengrui Pharma – Deploying AiTEM AI Formulation Platform at China’s Leading Drugmaker

Suzhou AsiFlyer Biotechnology Secures Exclusive Worldwide License from ShanghaiTech University for AI‑Designed Recombinant Botulinum Toxin Patent